SST2-positive Neuroendocrine Neoplasms
Oncology·MeSH: Neoplasm Metastasis
Prevalence
30.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1/Phase 2(1)
Frequently asked questions
How many drugs are in development for SST2-positive Neuroendocrine Neoplasms?
BioSniper tracks 1 drug in development for SST2-positive Neuroendocrine Neoplasms across 1 company.
How many clinical trials target SST2-positive Neuroendocrine Neoplasms?
There are 1 clinical trial targeting SST2-positive Neuroendocrine Neoplasms tracked by BioSniper.
What is the prevalence of SST2-positive Neuroendocrine Neoplasms?
The estimated prevalence of SST2-positive Neuroendocrine Neoplasms is approximately 30.0 per 100,000 population.
Deep-dive into SST2-positive Neuroendocrine Neoplasms
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis